CliffBio
biologic

Menactra

Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine

Loss of exclusivityJanuary 2017projected — 12-year biologic exclusivity estimate
CompanySanofi Vaccines US Inc.

Drug detail

Brand nameMenactra
Active ingredientMeningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Strength48UG/.5ML
Dosage formFor Injection
RouteIntramuscular
ModalityBiologic
FDA approvalJanuary 2005
Marketing statusRx

More from Sanofi Vaccines US Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Menactra patent cliff — loss of exclusivity January 2017 | CliffBio